Head-To-Head Analysis: Just Eat (OTCMKTS:JSTTY) & Eisai (OTCMKTS:ESALY)

Profitability

This table compares Just Eat and Eisai’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Just Eat	N/A	N/A	N/A
Eisai	4.11%	3.86%	2.50%

Earnings and Valuation

This table compares Just Eat and Eisai”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Just Eat	$1.04 billion	7.25	$110.39 million	N/A	N/A
Eisai	$6.74 billion	2.62	$426.79 million	$0.87	70.70

Eisai has higher revenue and earnings than Just Eat.

Risk & Volatility

Just Eat has a beta of -2.05, suggesting that its share price is 305% less volatile than the S&P 500. Comparatively, Eisai has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Eisai shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Eisai beats Just Eat on 7 of the 8 factors compared between the two stocks.

About Just Eat

Just Eat plc, together with its subsidiaries, operates a hybrid marketplace for online food delivery. The company enables consumers to order and pay for food from its restaurant partners. It serves approximately 26 million customers and 100,000 restaurant partners in the United Kingdom, Australia, New Zealand, Canada, Denmark, France, Ireland, Italy, Mexico, Norway, Spain, Switzerland, and Brazil. The company was founded in 2001 and is headquartered in London, the United Kingdom.

About Eisai

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.